Roivant Sciences Ltd. ROIV
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or "Vants" to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M | $23.8M | — |
| R&D | $681.8M | $550.4M | $439.9M | $454.1M | $483.0M | $236.6M | — |
| SG&A | $610.5M | $591.4M | $416.1M | $383.4M | $775.0M | $259.9M | — |
| Total operating expenses | $1.29B | $1.14B | $884.1M | $938.3M | $1.41B | $1.09B | — |
| Operating income | -$515.1M | -$1.00B | $4.50B | -$906.8M | -$1.35B | -$1.07B | — |
| Interest expense | — | — | $34.8M | $28.0M | $7.0M | $2.8M | — |
| Pre-tax income | -$264.6M | -$681.6M | $4.57B | -$885.0M | -$923.7M | -$898.5M | — |
| Income tax | $133.3M | $48.2M | $21.5M | $4.1M | $369.0K | $1.7M | — |
| Net income | -$397.9M | -$356.7M | $4.23B | -$1.12B | -$845.3M | -$809.2M | — |
| EPS, basic | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | — | — |
| EPS, diluted | -0.54 | -0.24 | 5.23 | -1.42 | -1.26 | -1.28 | — |
| Shares, diluted (wtd. avg.) | 693.9M | 725.4M | 831.0M | 712.8M | 669.8M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.42B | $2.72B | $6.49B | $1.68B | $2.07B | $2.14B | $2.27B |
| Short-term investments | $2.87B | $2.17B | $0 | — | — | — | — |
| Receivables | — | — | $53.5M | $30.4M | $3.9M | — | — |
| Inventory | — | — | $35.3M | $2.8M | $0 | — | — |
| Total current assets | $5.17B | $5.00B | $6.73B | $1.80B | $2.15B | $2.19B | — |
| Property, plant and equipment | $12.0M | $12.1M | $15.3M | $39.1M | $25.9M | $14.7M | — |
| Other intangibles | — | — | $137.8M | $144.9M | $0 | — | — |
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B | $2.59B | — |
| Accounts payable | $18.0M | $23.7M | $14.0M | $37.8M | $34.6M | $20.6M | — |
| Short-term debt | — | — | $12.0M | $40.7M | $0 | $0 | — |
| Total current liabilities | $281.2M | $149.4M | $266.8M | $272.4M | $184.4M | $219.0M | — |
| Long-term debt | — | — | $430.6M | $375.5M | $210.0M | $170.3M | — |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M | $527.7M | — |
| Retained earnings | -$501.8M | $116.1M | $576.2M | -$3.77B | -$2.76B | -$1.92B | — |
| Total equity | $4.53B | $4.69B | $6.45B | $1.61B | $2.04B | $2.04B | $2.09B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M | -$552.1M | — |
| Depreciation and amortisation | $3.3M | $14.1M | $22.0M | $18.9M | $5.9M | — | — |
| Stock-based compensation | $346.2M | $289.0M | $199.6M | $217.8M | $565.0M | $85.0M | — |
| Capital expenditure | $8.2M | $4.6M | $1.4M | $12.7M | $17.4M | $5.8M | — |
| Investing cash flow | -$682.3M | -$1.77B | $5.20B | -$44.3M | $303.3M | -$31.7M | — |
| Financing cash flow | $134.2M | -$1.22B | $419.4M | $499.5M | $306.8M | $456.3M | — |
| Buybacks | — | $1.29B | $0 | $0 | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-029955.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$809.2M | -$845.3M | -$1.12B | $4.23B | -$356.7M | -$397.9M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |